Drug-resistant tuberculosis

Current Opinion in Pulmonary Medicine

Volumn 19, Issue 3, 2013, Pages 266-272

  Pontali, Emanuele ^a   Matteelli, Alberto ^b   Migliori, Giovanni B ^c  

^a GALLIERA HOSPITAL   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Drug resistance; Extensive drug resistant tuberculosis; Multidrug resistant tuberculosis; Treatment of tuberculosis

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; BEDAQUILINE; CAPREOMYCIN; CILASTATIN PLUS IMIPENEM; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; DELAMANID; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; SPARFLOXACIN; STREPTOMYCIN; TERIZIDONE; THIOACETAZONE; UNINDEXED DRUG;

DRUG RESISTANT TUBERCULOSIS; HUMAN; INCIDENCE; LUNG TUBERCULOSIS; MORTALITY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; REVIEW;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84878109111     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32835f1bf3     Document Type: Review

References (56)

1. World Health Organization. Global tuberculosis control report. Geneva: World Health Organization; 2012 (WHO/HTM/TB/2012.6).
2. World Health Organization. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. WHO progress report. Geneva: World Health Organization; 2011. (WHO/HTM/TB/2011.3).
3. Zignol M, van Gemert W, Falzon D, et al. Surveillance of antituberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ 2012; 90:111-119D.
4. Matteelli A, Centis R, D'Ambrosio L, Migliori GB. Multidrug-resistant tuberculosis today. Bull World Health Organ 2012; 90:78.
5. Skrahina A, Hurevich H, Zalutskaya A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012; 39:1425-1431.
6. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. Eur Respir J 2012. doi:10.1183/09031936.00134712. [Epub ahead of print]
7. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond XDR-TB: results from a large individual patient data meta-analysis. Eur Respir J 2012. doi:10.1183/09031936.00136312. [Epub ahead of print]
8. Guidelines for the programmatic management of drug-resistant tuberculosis, emergency update 2008. (WHO/HTM/TB/2008.402). Geneva: World Health Organization; 2008.
9. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38:516-528.
10. Raviglione M, Marais B, Floyd K, et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 2012; 379:1902-1913.
11. Zumla A, Abubakar I, Raviglione M, et al. Drug-resistant tuberculosis - current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis 2012; 205 (Suppl. 2):S228-S240.
12. Migliori GB, Centis R, D'Ambrosio L, et al. Totally drug-resistant and extremely drug-resistant tuberculosis: the same disease? Clin Infect Dis 2012; 54:1379-1380.
13. Cegielski P, Nunn P, Kurbatova EV, et al. Challenges and controversies in defining totally drug-resistant tuberculosis. Emerg Infect Dis 2012; 18:e2; doi: 10.3201/eid1811.120526.
14. Jenkins HE, Plesca V, Ciobanu A, et al. Assessing spatial heterogeneity of MDR-TB in a high burden country. Eur Respir J 2012. doi:10.1183/09031936. 00111812. [Epub ahead of print]
15. Weyer K, Mirzayev F, Migliori GB, et al. Rapid molecular TB diagnosis: evidence, policy-making and global implementation of Xpert1MTB/RIF. Eur Respir J 2012. doi:10.1183/09031936.00157212. [Epub ahead of print]
16. Pantoja A, Fitzpatrick C, Vassall A, et al. Xpert MTB/RIF for the rapid diagnosis of TB and drug-resistant TB: a cost and affordability analysis. Eur Respir J 2012. doi:10.1183/09031936.00147912. [Epub ahead of print]
17. O'Grady J, Maeurer M, Mwabab P, et al. New and improved diagnostics for detection of drug-resistant pulmonary tuberculosis. Curr Opin Pulm Med 2011; 17:134-141.
18. Chang KC, Yew WW. Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012. Respirology 2013; 18:8-21.
19. O'Grady J, Bates M, Chilukutu L, et al. Evaluation of the Xpert MTB/RIF assay at a Tertiary Care Referral Hospital in a setting where tuberculosis and HIV infection are highly endemic. Clin Infect Dis 2012; 55:1171-1178.
20. World Health Organization. Policy statement. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Geneva: World Health Organization; 2011. http://whqlibdoc.who.int/publications/2011/ 9789241501545-eng.pdf.
21. Lawn SD, Zumla AI. Diagnosis of extrapulmonary tuberculosis using the Xpert(1) MTB/RIF assay. Expert Rev Anti Infect Ther 2012; 10:631-635.
22. Tortoli E, Russo C, Piersimoni C, et al. Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis. Eur Respir J 2012; 40:442-447.
23. Rachow A, Zumla A, Heinrich N, et al. Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay - a clinical validation study. PLoS One 2011; 6:e20458; doi: 10.1371/journal.pone. 0020458.
24. Yoon C, Cattamanchi A, Davis JL, et al. Impact of Xpert MTB/RIF testing on tuberculosis management and outcomes in hospitalized patients in Uganda. PLoS One 2012; 7:e48599; doi:10.1371/journal.pone.0048599. [Epub ahead of print].
25. Raviglione M, Zumla A, Marais B, et al. A sustainable agenda for tuberculosis control and research. Lancet 2012; 379:1077-1078.
26. Bates M, O'Grady J, Maeurer M, et al. Assessment of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in children in sub-Saharan Africa: a prospective descriptive study. Lancet Infect Dis 2013; 13:36-42.
27. Seddon JA, Godfrey-Faussett P, Jacobs K, et al. Hearing loss in patients on treatment for drug-resistant tuberculosis. Eur Respir J 2012; 40:1277-1286.
28. Isaakidis P, Varghese B, Mansoor H, et al. Adverse events among HIV/MDRTB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India. PLoS One 2012; 7:e40781; doi:10.1371/journal. pone.0040781.
29. Kurbatova EV, Gammino VM, Bayona J, et al. Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2012; 16:1335-1343.
30. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9:153-161.
31. Van Hest NAH, Ködmön C, Verver S, et al. Tuberculosis treatment outcome monitoring in European Union countries: systematic review. Eur Respir J 2012. doi:10.1183/09031936.00030612. [Epub ahead of print]
32. Leimane V, Dravniece G, Riekstina V, et al. Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004. Eur Respir J 2010; 36:584-593.
33. De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem/clavulanate added to linezolid containing regimens in the treatment of M/XDR-TB. Eur Respir J 2012. doi:10.1183/09031936.00124312. [Epub ahead of print]
34. Amaral L, Udwadia Z, Abbate E, van Soolingen D. The added effect of thioridazine in the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis 2012; 16:1706-1708.
35. Alsaad N, van Altena R, Pranger AD, et al. Evaluation of co-trimoxazole in treatment of multidrug-resistant tuberculosis. Eur Respir J 2012. doi 10.1183/09031936.00114812. [Epub ahead of print]
36. Wolff KA, Nguyen L. Strategies for potentiation of ethionamide and folate antagonists against Mycobacterium tuberculosis. Expert Rev Anti Infect Ther 2012; 10:971-981.
37. Jacobson KR, Tierney DB, Jeon CY, et al. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51:6-14.
38. Dey T, Brigden G, Cox H, et al. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2013; 68:284-293.
39. Xu HB, Jiang RH, Li L, Xiao HP. Linezolid in the treatment of MDR-TB: a retrospective clinical study. Int J Tuberc Lung Dis 2012; 16:358-363.
40. Rose PC, Hallbauer UM, Seddon JA, et al. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children. Int J Tuberc Lung Dis 2012; 12:1588-1593.
41. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40:1430-1442.
42. Gonzalo X, Drobniewski F. Is there a place for b-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate. J Antimicrob Chemother 2013; 68:366-369.
43. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9153 patients. PLoS Med 2012; 9:e1001300; doi: 10.1371/journal.pmed.1001300.
44. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrugresistant pulmonary tuberculosis. N Engl J Med 2012; 366:2151-2160.
45. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality for multidrug-resistant tuberculosis. Eur Respir J 2012. doi:10.1183/09031936.00125812. [Epub ahead of print]
46. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360:2397-2405.
47. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-Day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combination: a randomised trial. Lancet 2012; 380:986-993.
48. Lienhardt C, Raviglione M, Spigelman M, et al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis 2012; 205 (Suppl. 2):S241-249.
49. Grosset JH, Singer TG, Bissai WR. New drugs for the treatment of tuberculosis: hope and reality. Int J Tuberc Lung Dis 2012; 16:1005- 1014.
50. Upton AM. TBA-354: a next generation nitroimidazole for treatment of drug sensitive and drug-resistant tuberculosis [abstract]. In: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); San Francisco; 9-12 September 2012; abstr. 438.
51. Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: longterm outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012; 56:3271-3276.
52. Pontali E, Matteelli A, D'Ambrosio L, et al. Re-discovering high technology from the past: thoracic surgery is back on track for multi-drug resistant tuberculosis. Expert Rev Anti Infect Ther 2012; 10:1109-1115.
53. Man MA, Nicolau D. Surgical treatment to increase the success rate of multidrug-resistant tuberculosis. Eur J Cardiothorac Surg 2012; 42:e9-e12.
54. Raviglione MC, Lange C, Migliori GB. Preventing and managing antimicrobial resistance: an imperative for chest physicians. Eur Respir J 2011; 37:978- 981.
55. Migliori GB, Langendam MW, D'Ambrosio L, et al. Protecting the TB drug pipeline. Stating the case for the rational use of fluoroquinolones. Eur Respir J 2012; 40:814-822.
56. D'Ambrosio L, Centis R, Migliori GB. Multidrug-resistant tuberculosis. N Engl J Med 2012; 367:2154.